News

Most recently, Ms DeFilippo served as CFO and vice president of business development for the Guidant Cardiac Surgery business. Wick Goodspeed, president and CEO of FlowCardia, said: “Deborah

The pretargeted therapy involved TF10, a humanized bispecific antibody that binds to the same pancreatic cancer mucin as the antibody PAM4. TF10 was created by the company’s protein

Under conditions of the merger agreement, PacificGMP will receive funds to expand its operation in San Diego and assist in the development of the Taizhou facility and preparations

The Phase I trial is designed to assess the safety, tolerability and pharmacokinetics, as well as preliminary antitumor activity of TRC102 in patients with advanced cancer who also

Poly-ICR is a Toll-like Receptor 3 (TLR3) agonist that when combined with a disease-specific antigen can induce both cytotoxic (T-cell) and antibody (B-cell) immune responses against that antigen.

INOflo (brandname INOmax in the US) will be indicated for the treatment of newborns who suffer from hypoxic respiratory failure, a potentially life-threatening condition that keeps babies’ lungs

Franck Grimaud, CEO of Vivalis, said: “This new license confirms again that the EBx cell platform is a reference cell substrate for the industrial manufacture of viral vaccines.

The joint venture (JV) will provide a range of services in drug discovery research for international companies and research organizations seeking to develop and market pharmaceutical products and

This trial demonstrates PL 2100 Aspirin-PC may bridge to the safety and efficacy of aspirin for prescription (Rx) treatment and prevention of secondary prevention of stroke and myocardial